Literature DB >> 16600983

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.

R Hassan1, R Alexander, K Antman, P Boffetta, A Churg, D Coit, P Hausner, R Kennedy, H Kindler, M Metintas, L Mutti, M Onda, H Pass, A Premkumar, V Roggli, D Sterman, P Sugarbaker, R Taub, C Verschraegen.   

Abstract

Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.

Entities:  

Mesh:

Year:  2006        PMID: 16600983     DOI: 10.1093/annonc/mdl060

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  15 in total

1.  The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Authors:  Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert
Journal:  Mol Cancer Res       Date:  2019-11-15       Impact factor: 5.852

2.  The occurrence of rare cancers in U.S. adults, 1995-2004.

Authors:  Robert T Greenlee; Marc T Goodman; Charles F Lynch; Charles E Platz; Lori A Havener; Holly L Howe
Journal:  Public Health Rep       Date:  2010 Jan-Feb       Impact factor: 2.792

Review 3.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

Review 4.  Update on the management of malignant peritoneal mesothelioma.

Authors:  Paul H Sugarbaker
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 5.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

6.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.

Authors:  Aaron U Blackham; Edward A Levine
Journal:  European J Clin Med Oncol       Date:  2012-07

7.  Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.

Authors:  Paul H Sugarbaker
Journal:  Pleura Peritoneum       Date:  2017-05-23

8.  Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Authors:  B J Stish; S Oh; H Chen; A Z Dudek; R A Kratzke; D A Vallera
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 9.075

9.  Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma.

Authors:  Lana Bijelic; O Anthony Stuart; Paul Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-08-08       Impact factor: 2.260

10.  Malignant peritoneal mesothelioma diagnosed by EUS-guided tissue acquisition.

Authors:  Dai Mohri; Yousuke Nakai; Hiroyuki Isayama; Kazuhiko Koike
Journal:  Endosc Ultrasound       Date:  2015 Oct-Dec       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.